This time the digital desk: The AstraZeneca vaccine is being introduced in India under the name Covishield. Recent research has shown that this vaccine Platelets The chances of a count reduction are slightly higher. The researchers said that public health authorities should be aware of the relatively increased risks associated with the ChAdOx1 vaccine.

However, no such risk has been reported in Pfizer – BioNTech’s mRNA vaccine. The study was published in the journal Nature Medicine. In Scotland Vaccine The study was conducted on people who took the Covid-19 vaccine in Scotland between 8 December 2020 and 14 April 2021. Which is 56.5 percent adult citizens of that country.
Of these, 17.1 million people have received the AstraZeneca vaccine. On the other hand, 7.2 lakh people got the Pfizer – BioNTech vaccine. In addition, less than 10,000 people have received the Moderna vaccine.

These 3 types of people may have side effects after taking the COVID vaccine! Says research.
A team from the University of Edinburgh reported that 1.3 out of every 100,000 people were diagnosed with thrombocytopenia in the first six days of use of the AstraZeneca vaccine. In thrombocytopenia, the platelet count in the blood decreases. As a result, there is a problem in blood clotting.
Researchers also say that 1.13 out of every 100,000 people are likely to develop immune thrombocytopenic purpura (ITP) within 28 days of receiving the AstraZeneca vaccine. In this disease of the blood, the number of platelets in the blood decreases. Studies have shown that those who have ITP after the ChAdOx1 vaccine are more likely to be hospitalized due to a single clinical condition than those with pre-existing ITP.

The researchers said that the AstraZeneca vaccine not only reduced the number of platelets but also caused blood clots in the arteries up to 20 days after the first dose of the vaccine. This is 5.6 times more common in people under the age of 39 who have been vaccinated per 1 lakh.